AI Article Synopsis
- The study aimed to compare the costs of Essure hysteroscopic sterilization performed in an office setting versus laparoscopic sterilization done in an operating room.
- Cost analysis revealed that laparoscopic tubal ligations averaged $3449, whereas the Essure device placement was significantly cheaper at $1374, highlighting a $2075 cost difference.
- The conclusion suggests that, at this institution, hysteroscopic placement of the Essure device is a more cost-effective option for permanent sterilization compared to laparoscopic methods.
Article Abstract
Study Objective: To evaluate the actual cost difference in performing Essure hysteroscopic sterilization in the office compared with ambulatory surgery using laparoscopic sterilization in the operating room.
Design: Cost-comparison analysis (Canadian Task Force classification III).
Setting: University hospital and affiliated outpatient office.
Interventions: Hysteroscopic placement of Essure device in an office setting and laparoscopic tubal ligation for permanent sterilization.
Measurements And Main Results: The various costs associated with the two procedures at our institution were compiled, and a direct cost comparison was made. We used actual institutional costs of the procedures, not billing or reimbursement. We found laparoscopic tubal ligations to cost 3449 dollars compared with hysteroscopic placement of the Essure device that costs 1374 dollars yielding a 2075 dollars difference between the procedures.
Conclusion: In our institution and in our experience, office-hysteroscopic placement of the Essure device is a more cost-effective method than laparoscopic tubal ligation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jmig.2005.05.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes after a Uterine-Sparing Approach to Essure Contraceptive Device Removal.
JSLS
December 2022
Division of Minimally Invasive Gynecologic Surgery, Department of Obstetrics & Gynecology and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.
Background And Objective: To analyze long-term effectiveness of a conservative, uterine-sparing approach to laparoscopic Essure removal. Specific outcomes of interest include patient satisfaction, symptom resolution, and subsequent surgical intervention.
Methods: A retrospective case series and follow-up survey.
Release of metal elements from the Essure implant: A prospective cohort study.
Eur J Obstet Gynecol Reprod Biol
June 2022
Department of Gynecology, Hôpital Femme Mère Enfant, HFME, 59 boulevard Pinel, University Hospital of Lyon, 69500 Bron, France; University Claude Bernard of Lyon 1, EMR 3738 CICLY, 69000 Lyon, France. Electronic address:
Objective(s): The causal mechanistic relationships between Essure® and adverse effects are unclear, but corrosion in the in-vivo environment with release of metal ions may be suspected. Here we evaluated the concentrations of nickel (Ni), chromium (Cr) and tin (Sn) in the peritoneal fluid (PF) and in the fallopian tube (FT) during laparoscopic Essure® removal compared to a control group.
Study Design: Ni, Cr and Sn concentrations were determined in the PF and FT from two groups(group A: symptomatic patients with Essure®) vs group B (control group without Essure®) by Inductively Coupled Plasma Mass Spectrometry analysis.
Could the anatomic location of Essure® device explain the impairment of quality of life?
Minerva Obstet Gynecol
April 2022
Department of Gynecology, Hôpital Femme Mère Enfant - HFME, University of Lyon, Lyon, France.
Background: Since health-related quality of life (HRQL) could improve after removal of Essure (Bayer, Leverkusen, Germany) inserts in symptomatic patients, we aimed to assess whether such postoperative enhancement was linked to the anatomic placement of the device.
Methods: Correct and incorrect placed Essure (Bayer) were identified in the electronic database of the French cohort Ablimco (cohort of consenting patients with laparoscopic Essure [Bayer] removal). HRQL, pain and heavy menstrual bleeding were evaluated after Essure (Bayer) removal with validated quality of life questionnaires (Short Form12 Questionnaire, Visual Analogue Scale, French version of the McGill Pain Questionnaire and the pictorial blood assessment chart PBAC).
Interstitial Ectopic Pregnancy in a 34-Year-Old Woman After Removal of Essure Microinserts and Reversal of Hysteroscopic Sterilization.
Am J Case Rep
April 2022
Department of Reproductive Endocrinology & Infertility, University of Cincinnati, College of Medicine, West Chester, OH, USA.
BACKGROUND Interstitial ectopic pregnancy, a pregnancy occurring in the part of the fallopian tube that is within the body of the uterus, poses a significant risk to patients, with a mortality rate of up to 2.5%, which is 7 times higher than for tubal ectopic pregnancies. Hysteroscopic sterilization reversal carries a potential risk of interstitial ectopic pregnancy; therefore, it is important to counsel patients appropriate and review the alternative option for in vitro fertilization.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!